 |
 |
 |
 |
 |
|
|||||
|
Select Publications
Alberts DS et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26):1950-5. Abstract
Armstrong DK et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 172). Proc ASCO 2002;Abstract 803.
Cannistra SA et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6. Abstract
Ferrandina G et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26(6):890-6. Abstract
Han ES et al. Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study. Proc ASCO 2007;Abstract 21021.
Konner JA et al. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer.
Proc ASCO 2007;Abstract 5523.
Markman M et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19(4):1001-7. Abstract
Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 1992;10(4):513-4. No abstract available.
McGuire WP et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1995;13(7):1589-99. Abstract
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Deborah K Armstrong, MD
- Select publications
David R Spriggs, MD
- Select publications
Robert L Coleman, MD
- Select publications
Ovarian Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
  |
